These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11761227)

  • 1. Evaluating the oncogenic risk of residual DNA in vaccines: the potential role of transgenic mice.
    Onions D
    Dev Biol (Basel); 2001; 106():135-42; discussion 143-60. PubMed ID: 11761227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Runx genes: lineage-specific oncogenes and tumor suppressors.
    Cameron ER; Neil JC
    Oncogene; 2004 May; 23(24):4308-14. PubMed ID: 15156187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model.
    Rounbehler RJ; Rogers PM; Conti CJ; Johnson DG
    Cancer Res; 2002 Jun; 62(11):3276-81. PubMed ID: 12036945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma.
    Wotton S; Stewart M; Blyth K; Vaillant F; Kilbey A; Neil JC; Cameron ER
    Cancer Res; 2002 Dec; 62(24):7181-5. PubMed ID: 12499254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors.
    Reamon-Buettner SM; Borlak J
    Cancer Res; 2008 Sep; 68(18):7587-96. PubMed ID: 18794147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression phenotypic models that predict the activity of oncogenic pathways.
    Huang E; Ishida S; Pittman J; Dressman H; Bild A; Kloos M; D'Amico M; Pestell RG; West M; Nevins JR
    Nat Genet; 2003 Jun; 34(2):226-30. PubMed ID: 12754511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RUNX genes: gain or loss of function in cancer.
    Blyth K; Cameron ER; Neil JC
    Nat Rev Cancer; 2005 May; 5(5):376-87. PubMed ID: 15864279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic mice as an in vivo model of lymphomagenesis.
    Tarantul VZ
    Int Rev Cytol; 2004; 236():123-80. PubMed ID: 15261738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic potential of the RUNX gene family: 'overview'.
    Ito Y
    Oncogene; 2004 May; 23(24):4198-208. PubMed ID: 15156173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proviral activation of the tumor suppressor E2a contributes to T cell lymphomagenesis in EmuMyc transgenic mice.
    Mikkers H; Allen J; Berns A
    Oncogene; 2002 Sep; 21(43):6559-66. PubMed ID: 12242653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cbfbeta interacts with Runx2 and has a critical role in bone development.
    Kundu M; Javed A; Jeon JP; Horner A; Shum L; Eckhaus M; Muenke M; Lian JB; Yang Y; Nuckolls GH; Stein GS; Liu PP
    Nat Genet; 2002 Dec; 32(4):639-44. PubMed ID: 12434156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of collaborating oncogenes in compound mutant mice.
    Berns A; Mikkers H; Krimpenfort P; Allen J; Scheijen B; Jonkers J
    Cancer Res; 1999 Apr; 59(7 Suppl):1773s-1777s. PubMed ID: 10197595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Runx genes in chondrocyte differentiation.
    Stricker S; Fundele R; Vortkamp A; Mundlos S
    Dev Biol; 2002 May; 245(1):95-108. PubMed ID: 11969258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Core-binding factor beta interacts with Runx2 and is required for skeletal development.
    Yoshida CA; Furuichi T; Fujita T; Fukuyama R; Kanatani N; Kobayashi S; Satake M; Takada K; Komori T
    Nat Genet; 2002 Dec; 32(4):633-8. PubMed ID: 12434152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting oncogenes.
    Goodman L
    J Clin Invest; 2004 Nov; 114(10):1362. PubMed ID: 15545982
    [No Abstract]   [Full Text] [Related]  

  • 16. Conservation and expression of an alternative 3' exon of Runx2 encoding a novel proline-rich C-terminal domain.
    Terry A; Kilbey A; Vaillant F; Stewart M; Jenkins A; Cameron E; Neil JC
    Gene; 2004 Jul; 336(1):115-25. PubMed ID: 15225881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
    Choe C; Chen N; Sawadogo M
    Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Activation of multiple tumor suppressor genes by MBD1 siRNA in pancreatic cancer cell line BxPC-3].
    Xu J; Liu C; Yu XJ; Jin C; Fu DL; Ni QX
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1948-51. PubMed ID: 19062732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of tumor progression by transcriptional profiling of mouse MK16 cell lines transformed with human papillomavirus type 16 E6 and E7 oncogenes and activated H-ras.
    Smahel M; Smahelová J; Tejklová P; Tachezy R; Jelínek F
    Oncol Rep; 2005 Dec; 14(6):1665-74. PubMed ID: 16273273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy.
    Unruh A; Ressel A; Mohamed HG; Johnson RS; Nadrowitz R; Richter E; Katschinski DM; Wenger RH
    Oncogene; 2003 May; 22(21):3213-20. PubMed ID: 12761491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.